These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 23132043

  • 1. The risks associated with aprotinin use: a retrospective study of cardiac cases in Nova Scotia.
    Riddell RE, Buth KJ, Sullivan JA.
    Can J Anaesth; 2013 Jan; 60(1):16-23. PubMed ID: 23132043
    [Abstract] [Full Text] [Related]

  • 2. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
    Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R.
    Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
    [Abstract] [Full Text] [Related]

  • 3. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
    Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS.
    Anesth Analg; 2010 Jan 01; 110(1):21-9. PubMed ID: 19910626
    [Abstract] [Full Text] [Related]

  • 4. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.
    Later AF, Maas JJ, Engbers FH, Versteegh MI, Bruggemans EF, Dion RA, Klautz RJ.
    Eur J Cardiothorac Surg; 2009 Aug 01; 36(2):322-9. PubMed ID: 19250838
    [Abstract] [Full Text] [Related]

  • 5. Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.
    Jakobsen CJ, Søndergaard F, Hjortdal VE, Johnsen SP.
    Eur J Cardiothorac Surg; 2009 Nov 01; 36(5):863-8. PubMed ID: 19782573
    [Abstract] [Full Text] [Related]

  • 6. Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.
    Maslow AD, Chaudrey A, Bert A, Schwartz C, Singh A.
    J Cardiothorac Vasc Anesth; 2008 Feb 01; 22(1):6-15. PubMed ID: 18249324
    [Abstract] [Full Text] [Related]

  • 7. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
    Casati V, Guzzon D, Oppizzi M, Bellotti F, Franco A, Gerli C, Cossolini M, Torri G, Calori G, Benussi S, Alfieri O.
    J Thorac Cardiovasc Surg; 2000 Sep 01; 120(3):520-7. PubMed ID: 10962414
    [Abstract] [Full Text] [Related]

  • 8. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis.
    Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C.
    Crit Care; 2010 Sep 01; 14(4):R148. PubMed ID: 20682059
    [Abstract] [Full Text] [Related]

  • 9. Aprotinin in cardiac surgery patients: is the risk worth the benefit?
    Stamou SC, Reames MK, Skipper E, Stiegel RM, Nussbaum M, Geller R, Robicsek F, Lobdell KW.
    Eur J Cardiothorac Surg; 2009 Nov 01; 36(5):869-75. PubMed ID: 19782574
    [Abstract] [Full Text] [Related]

  • 10. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination?
    Bulutcu FS, Ozbek U, Polat B, Yalçin Y, Karaci AR, Bayindir O.
    Paediatr Anaesth; 2005 Jan 01; 15(1):41-6. PubMed ID: 15649162
    [Abstract] [Full Text] [Related]

  • 11. Coronary artery bypass grafting after aprotinin: are we doing better?
    Beckerman Z, Shopen Y, Alon H, Cohen O, Nir RR, Adler Z, Bolotin G.
    J Thorac Cardiovasc Surg; 2013 Jan 01; 145(1):243-8. PubMed ID: 23072702
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients.
    Martin K, Wiesner G, Breuer T, Lange R, Tassani P.
    Anesth Analg; 2008 Dec 01; 107(6):1783-90. PubMed ID: 19020118
    [Abstract] [Full Text] [Related]

  • 14. Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
    Vonk AB, Meesters MI, Schats J, Romijn JW, Jansen EK, Boer C.
    Interact Cardiovasc Thorac Surg; 2011 Feb 01; 12(2):135-9. PubMed ID: 21075830
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints.
    Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briët E, Büller HR.
    Lancet; 1999 Dec 04; 354(9194):1940-7. PubMed ID: 10622296
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of tranexamic acid compared with aprotinin in thoracic aortic surgery with deep hypothermic circulatory arrest.
    Nicolau-Raducu R, Subramaniam K, Marquez J, Wells C, Hilmi I, Sullivan E.
    J Cardiothorac Vasc Anesth; 2010 Feb 04; 24(1):73-9. PubMed ID: 19717314
    [Abstract] [Full Text] [Related]

  • 18. The risk associated with aprotinin in cardiac surgery.
    Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation.
    N Engl J Med; 2006 Jan 26; 354(4):353-65. PubMed ID: 16436767
    [Abstract] [Full Text] [Related]

  • 19. Tranexamic acid versus ɛ-aminocaproic acid: efficacy and safety in paediatric cardiac surgery.
    Martin K, Breuer T, Gertler R, Hapfelmeier A, Schreiber C, Lange R, Hess J, Wiesner G.
    Eur J Cardiothorac Surg; 2011 Jun 26; 39(6):892-7. PubMed ID: 21115357
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.